Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

CYTX / Cytori Therapeutics, Inc. 8-K (Current Report)

14h sec.gov
cytx-8k_20180221.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  February 21, 2018   CYTORI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)     Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. (20-0)

CYTX / Cytori Therapeutics, Inc. 8-K (Current Report)

2018-02-09 sec.gov
cytx-8k_20180205.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  February 5, 2018   CYTORI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)     Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

CYTX / Cytori Therapeutics, Inc. / Postfinance Ag - SC 13G (Passive Investment)

2018-02-02 sec.gov
SC 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.     )* Cytori Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23283K204 (CUSIP Number) January 31, 2018 (Date of Event which Requires filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * The r

CYTX / Cytori Therapeutics, Inc. / Postfinance Ag - SC 13G (Passive Investment)

2018-02-02 sec.gov
SC 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.     )* Cytori Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23283K204 (CUSIP Number) January 31, 2018 (Date of Event which Requires filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * The r

BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board

2018-01-29 reuters
* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD (25-2)

CYTX / Cytori Therapeutics, Inc. 8-K (Current Report)

2018-01-29 sec.gov
cytx-8k_20180125.DOCX.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  January 25, 2018   CYTORI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)     Delaware 001-34375 33-0827593 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

CYTX / Cytori Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-08 fintel.io
Cytori Therapeutics, Inc. (NASDAQ:CYTX) has 36 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,170,752 shares. Largest shareholders include Swissquote Bank Sa, Sabby Management, LLC, Perkins Capital Management Inc, Vanguard Group Inc, BlackRock Inc., Geode Capital Management, Llc, Renaissance Technologies LLC, Creative Planning, Northern Trust Corp, and UBS Group AG. (61-1)

CYTX / Cytori Therapeutics, Inc. / Swissquote Bank Sa - SC 13G (Passive Investment)

2018-01-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Cytori Therapeutics, Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   23283K204 (CUSIP Number)   December 29, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this

CYTX / Cytori Therapeutics, Inc. / Swissquote Bank Sa - SC 13G (Passive Investment)

2018-01-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Cytori Therapeutics, Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   23283K204 (CUSIP Number)   December 29, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this

CYTX / Cytori Therapeutics, Inc. / Sabby Management, LLC - SABBY 13G-A CYTX 1.04.18 (Passive Investment)

2018-01-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* Cytori Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23283K204 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder o

CYTX / Cytori Therapeutics, Inc. / Sabby Management, LLC - SABBY 13G-A CYTX 1.04.18 (Passive Investment)

2018-01-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* Cytori Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23283K204 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder o

CYTX / Cytori Therapeutics, Inc. / Azaya Therapeutics Inc - SC 13G/A (Passive Investment)

2018-01-04 sec.gov
          UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)   Cytori Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23283K204 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d)  

CYTX / Cytori Therapeutics, Inc. / Azaya Therapeutics Inc - SC 13G/A (Passive Investment)

2018-01-04 sec.gov
          UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)   Cytori Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23283K204 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d)  

CYTX / Cytori Therapeutics, Inc. ESP

2018-01-01 sec.gov
cytx-corresp.htm   Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121     November 1, 2017   VIA EDGAR   Tom Jones Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549   Re:     Cytori Therapeutics, Inc. Registration Statement on Form S-1 Filed August 14, 2017 File No. 333-219967   Dear Mr. Jones:   Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the unders

CYTX / Cytori Therapeutics, Inc. FORM 8-A12B

2017-11-28 sec.gov
cytx-8k_20171128.DOCX.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-A   FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934       CYTORI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)               Delaware   33-0827593 (State of incorporation or organization)   (I.


CUSIP: 23283K121